Alder Biopharmaceuticals Received its Third Buy in a Row


After RBC Capital and Mizuho Securities gave Alder Biopharmaceuticals (NASDAQ: ALDR) a Buy rating last month, the company received another Buy, this time from Needham. Analyst Danielle Brill maintained a Buy rating on Alder Biopharmaceuticals (NASDAQ: ALDR) today and set a price target of $28. The company’s shares closed yesterday at $16.

Brill has an average return of 28.4% when recommending Alder Biopharmaceuticals.

According to TipRanks.com, Brill is ranked #647 out of 4822 analysts.

Alder Biopharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $23.17, which is a 44.8% upside from current levels. In a report issued on June 13, Canaccord Genuity also maintained a Buy rating on the stock with a $20 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $19.35 and a one-year low of $8.60. Currently, Alder Biopharmaceuticals has an average volume of 1.08M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Alder Biopharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company, which discovers, develops, and commercializes various therapeutic antibodies. Its product portfolio includes ALD1910, a preclinical product candidate also in development as a migraine prevention therapy.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts